Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
December 12, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 28, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 14, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 07, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
November 02, 2023 10:37 ET
|
Onconova Therapeutics, Inc.
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...
Onconova Expands Leadership Team with Two Key Appointments
October 24, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
October 19, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE...
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
August 10, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with...